A Study to Test the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK1006 (MK-1006-002)(COMPLETED)
Condition: Type 2 Diabetes Mellitus
MeSH terms: Diabetes Mellitus, Type 2
Intervention: MK1006; Placebo
Intervention description: MK1006 capsules: 1 mg, 10 mg, and 20 mg.
Panel A: MK1006 capsules in five doses beginning at 15 mg and rising to 60 mg
Panel B: MK1006 capsules in five doses beginning at 60 mg and rising to 140 mg.
Panel C: MK1006 capsules in five doses beginning at 140 mg and rising to 260 mg.
There will a 7-day interval between each dose; Placebo capsule to match MK1006 1, 10, and 20 mg.
Panel A: Placebo to MK1006 capsules in five doses beginning at 15 mg and rising to 60 mg
Panel B: Placebo to MK1006 capsules in five doses beginning at 60 mg and rising to 140 mg.
Panel C: Placebo to MK1006 capsules in 5 doses beginning at 140 mg and rising to 260 mg.
There will a 7-day interval between each dose
Phase: Phase 1
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Double (Participant, Investigator)
Enrollment: 25.0
Sex: All
Minimum age: 18 Years
Maximum age: 55 Years
Healthy volunteers: No

Summary:

      This study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of
      single doses of MK1006
    

Eligibility criteria:

        Inclusion Criteria:

          -  Participant is between 18 and 55 years of age. Participants up to 65 years of age may
             be enrolled in Panels B and C

          -  Female participants must be postmenopausal or otherwise unable to have children

          -  Participant has a body mass index (BMI) less than or equal to 42 kg/m^2 at the
             screening visit

          -  Participant has type 2 diabetes and is being treated with either diet and exercise or
             a single oral anti-hyperglycemic medication. For Panels B and C, participant may be
             treated with combination oral anti-hyperglycemic medications

          -  Participant is willing to follow the American Heart Association (AHA) diet and
             exercise program throughout the study

          -  Participant is a nonsmoker or has not used nicotine-containing products for 6 months
             prior to study start

        Exclusion Criteria:

          -  Participant has a history of stroke, seizures, or other neurological disorders

          -  Participant has a recent history of eye infection or other inflammatory eye conditions

          -  Participant has glaucoma or is blind

          -  Participant has had eye surgery within 6 months of study start (Lasik is permitted)

          -  Participant has type 1 diabetes

          -  Participant cannot stop taking any of their current prescription or non-prescription
             medications during the study

          -  Participant consumes more than 3 alcoholic beverages per day

          -  Participant consumes more than 6 caffeinated beverages per day

          -  Participant has had major surgery or has donated blood within 4 weeks of study start

          -  Participant has multiple and/or severe allergies to drugs or food